Morgan Stanley Galecto, Inc. Put Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding GLTO
# of Institutions
13Shares Held
442KCall Options Held
100Put Options Held
100About Galecto, Inc.
- Ticker GLTO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,395,700
- Market Cap $172M
- Description
- Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...